Lessons from COVID-19 to increase opioid vaccine acceptance

Roxana Damiescu; Mita Banerjee; Norbert W Paul; Thomas Efferth

doi:10.1016/j.tips.2022.08.010

Lessons from COVID-19 to increase opioid vaccine acceptance

Trends Pharmacol Sci. 2022 Dec;43(12):998-1000. doi: 10.1016/j.tips.2022.08.010. Epub 2022 Sep 7.

Authors

Roxana Damiescu¹, Mita Banerjee², Norbert W Paul³, Thomas Efferth⁴

Affiliations

¹ Department of Pharmaceutical Biology, Institute of Pharmaceutical and Biomedical Sciences, Johannes Gutenberg University, Staudinger Weg 5, Mainz, Germany.
² Department of English and Linguistics, American Studies, Johannes Gutenberg University, Mainz, Germany.
³ Institute for History, Philosophy, and Ethics of Medicine, Johannes Gutenberg University Medical Center, Mainz, Germany.
⁴ Department of Pharmaceutical Biology, Institute of Pharmaceutical and Biomedical Sciences, Johannes Gutenberg University, Staudinger Weg 5, Mainz, Germany. Electronic address: efferth@uni-mainz.de.

Abstract

COVID-19 has put vaccine efficacy under a spotlight. However, the reluctance of people to be vaccinated has postponed the end of the COVID-19 pandemic. Currently, opioid vaccines are being developed, which could help prevent opioid addiction, overdoses, or relapse in combination with medication-assisted therapy. The fear is that the uptake of opioid vaccines could be met by the same reluctance as seen with COVID-19 vaccines.

Trial registration: ClinicalTrials.gov NCT04458545.

Keywords: COVID-19 vaccination; opioid misuse; opioid vaccination; public health; vaccine reluctance.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Analgesics, Opioid
COVID-19 Vaccines
COVID-19* / prevention & control
Humans
Pandemics / prevention & control
Vaccines*

Substances

COVID-19 Vaccines
Analgesics, Opioid
Vaccines

Associated data

ClinicalTrials.gov/NCT04458545